FDA Investigator Kathleen B Mihalik
Kathleen B Mihalik has conducted inspections on 1 sites in 1 countries as of 14 Oct 2022. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
1
Last Inspection Date:
14 Oct 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Kathleen B Mihalik:
Alla Kachko, PhD,
Anastasia I Offordile,
Anissa M Cheung,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ann Marie Schofield,
Audrey Thereset Uy,
Brentley S Collins,
Brian S Keefer,
CDR Jeremy L Wally, PhD,
Chao Ming Tsai,
Christian D Lynch (CDL),
Christina J Sauder, PhD,
Christopher J Adams,
Craig D Zagata,
Cynthia Jim, CSO,
Dave Hafner,
David J Hafner,
Debra J Bennett,
Debra L Pagano,
Eileen A Liu,
Ellen Huang,
Gene D Arcy,
Hala L Selby,
Haruhiko Murata,
Helen B Ricalde,
J David Doleski,
Jacqueline Mdiaz Albertini,
James M Mason,
Joan A Loreng,
Joan Adamo,
Joanne M Hajoway,
Joseph George,
Julianne C Mccullough,
Junho Pak,
Karyn M Campbell,
Kathryn Carbone, MD,
Kelly N Kerr,
Kenneth M Gordon,
Kristen D Evans,
LCDR Margaret Edi Gennaro,
Linda Thai,
Lisa M Bellows,
Lisa M Feola,
LT John M Mastalski,
Marian E Major, PhD,
Michael Curbarg,
Michael Gurbarg,
Mihaly S Ligmond,
Omotunde O Osunsanmi,
Paula A Trost,
Prabhu P Raju,
Ramon E Martinez,
Rebecca K Olin,
Robert B Shibuya, MD,
Robert D Tollefsen,
Rose Ashley,
Scott E Norris,
Sheila Dreher Lesnick,
Shuang Tang,
Simone E Pitts,
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Steven A Rubin,
Susan F Laska, MS,
Tammy L Chavis,
Tina S Roecklein,
Vlada Matusovsky,
Wei Wang, PhD,
Xiao Wang
Kathleen B Mihalik's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2000 | EIR | Merck Sharp & Dohme LLC - EIR, 2000-10-11 |
October, 2000 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2000-10-11 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more